March 14, 2017

Solid Honors Rare Disease Day 2017

Solid Biosciences is proud to join the global Rare Disease community to recognize Rare Disease Day 2017. Sponsored by EURORDIS on the last day of February each year, Rare Disease Day raises awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.

In our mission to end Duchenne muscular dystrophy, we understand how important it is to work together with the entire Rare Disease community – researchers, fellow companies, government and families – to bring forward new innovations and effect true change.

This year, we were honored to participate in the conversation in several ways, including attending MassBio’s Rare Disease Day 2017 Massachusetts State House event and the Jett Foundation’s 2nd annual Rare Disease luncheon. In addition, our team sported their best jeans to support the Global Gene’s Wear That Your Care® campaign.

Related news


Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET


- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -


Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


More information about Solid?

Please subscribe to receive our latest news